Financial business

NMRD) publishes a financial and commercial report for the second quarter of 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the development and commercialization of portable, non-invasive diagnostic devices and support for personalized lifestyle coaching programs, has released its financial and business updates for the second quarter of the fiscal year 2022, the period ending September 30, 2021. Notable highlights include the launch of Miboko, the company’s consumer metabolic health beta program and the signing of a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP “). In addition, the company has appointed Dr Osama Hamdy, MD and PhD., As a new consultant within its advisory board as a consultant. Regarding the financial report, the company said total operating expenses estimated at $ 1.7 million, cash equivalents of about $ 26.8 million and the submission to its UK licensee a first “deposit invoice” of $ 513,000 in partial payment of the order received for 200,000 sensors. and associated devices. “We continue to make progress in our marketing efforts for sugarBEAT (R) in the UK and recognizing our licensee’s income, ”Nemaura Medical CEO Dr Faz Chowdhury said in the press release. “We are also working closely with advisors to expand our presence globally to address the global diabetes health crisis by using our skin-mounted needle-free CGM as an innovative solution for patients and consumers. Combined with our digital lifestyle management programs, we believe our technology offering has the potential to be a key tool for the prevention and management of type 2 diabetes. ”

To view the full press release, visit

About Nemaura Médical inc.

Nemaura Medical is a medical technology company that develops and markets portable, non-invasive diagnostic devices. The company currently markets sugarBEAT (R) and proBEAT (TM). sugarBEAT, a CE Mark approved Class IIb medical device, is a non-invasive and flexible Continuous Glucose Monitor (“CGM”) that provides actionable information derived from real-time blood glucose readings and daily trend data blood sugar levels, which can help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a pre-market approval (“PMA”) request for sugarBEAT to the United States Food and Drug Administration (“FDA”). proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and was launched in the United States as a general wellness product in the part of NMRD’s BEAT diabetes program. Nemaura sits at the intersection of the global type 2 diabetes market expected to reach nearly $ 59 billion by 2025, the prediabetics market of over $ 50 billion, and the wearable health technology industry for weight loss and wellness apps which is expected to reach $ 60. billion by 2023. For more information about the company, visit

NOTICE TO INVESTORS: The latest news and updates related to NMRD can be found in the company newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements delivered in multiple languages, we’ve got the wire-quality delivery products you’ll need to make sure your next press release grabs the attention of your target audience and doesn’t let go. While our competitors seek to offer you hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all national outings. While other communications services can provide a basic review of your release, InvestorWire helps you do your best with Improved press release.

At our competitors, the job is done the second your exit goes on the wire. Not with InvestorWire. We include follow-up coverage of each release taking advantage of the ever-growing audience for the 50+ brands who make up the InvestorBrandNetwork.

Make the most of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please review the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever posted or republished:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, California 90046
310.299.1717 Office
[email protected]

InvestorWire is part of InvestorBrandNetwork.